Abstract
The possibility to repair injured donor livers during ex situ machine perfusion might increase the utilization of ECD-livers. Application of defatting agents is currently explored in clinical trials, whereas other therapeutics require further research or optimization before entering clinical research.
| Original language | English |
|---|---|
| Pages (from-to) | 248-254 |
| Number of pages | 7 |
| Journal | Current Opinion in Organ Transplantation |
| Volume | 29 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2024 |
Bibliographical note
Publisher Copyright:© 2024 Lippincott Williams and Wilkins. All rights reserved.